How to Improve Access to CAR T-cell Therapy: The Role of Policy and Innovation

ONCOLife presents an exclusive interview with Dr. John Gribben, Professor at the Cancer Institute in London. In this session, we explore the clinical and systemic landscape of CAR T-cell therapy — a treatment offering hope to patients with aggressive blood cancers. Dr. Gribben shares expert insights into the current access gaps, and discusses what must change to ensure more eligible patients can benefit from this potentially curative therapy.  You can also follow this interview on LinkedIn using this link:>>>

He highlights the importance of aligning clinical practice with policy reform, the need for real-world data to support health technology assessments, and the steps needed to build treatment capacity as indications expand. We also discuss the CAR T Vision initiative’s ambitious goal to double access to CAR T-cell therapy by 2030, and how healthcare systems must act with urgency to turn this vision into reality.

Some of the main topics in this interview include:

✔️ The current state and future potential of CAR T-cell therapy in oncology
✔️ Key systemic barriers limiting access to treatment
✔️ The role of policy, innovation, and real-world evidence in expanding access
✔️ How to prepare health systems for broader use of CAR T-cell therapy
✔️ The strategic vision to double CAR T-cell access by 2030